Lonza is to carry out process development and manufacture of Micromet’s clinical-stage CD19-targeting BiTE antibody, blinatumomab (MT103). Under terms of the deal Lonza will manufacture blinatumomab for clinical trials, develop a commercial-scale process, and supply commercial quantities of the drug if requested.


Blinatumomab is a lymphoma-directed, recombinant bispecific single-chain antibody generated using Micromet’s BiTE® antibody technology. The candidate is currently undergoing Phase II trials in acute lymphoblastic leukemia, and a Phase I trial in non-Hodgkin lymphoma.








This site uses Akismet to reduce spam. Learn how your comment data is processed.